Cassava Sciences Inc

NASDAQ:SAVA   3:59:59 PM EDT
43.88
+2.96 (+7.23%)
Products, Regulatory

Cassava Sciences Announces Final Results Of Phase 2B Clinical Study Of Sumifilam In Patients With Alzheimer’S Disease

Published: 09/14/2020 12:20 GMT
Cassava Sciences Inc (SAVA) - Cassava Sciences Announces Final Results of a Phase 2b Clinical Study of Sumifilam in Patients With Alzheimer’s Disease.
Cassava Sciences Inc - Sumifilam Was Safe and Well-tolerated.
Cassava Sciences- Alzheimer's Patients in Drug Groups Showed Statistically Significant Improvements in Biomarkers of Disease Compared to Placebo Group.
Cassava Sciences Inc - Alzheimer's Patients in Drug Groups Showed Improved Cognition Compared to Placebo Group.
Cassava Sciences Inc - Alzheimer's Patients Treated With Sumifilam Showed Directional Improvements in Tests of Remembering New Information.